Strong inhibition of insulin/IGF-1 signaling in early-mid adulthood compresses morbidity, but in later life accelerates aging
This study demonstrates that while strong inhibition of insulin/IGF-1 signaling during early-to-mid adulthood compresses morbidity and extends lifespan, the optimal strategy for maximizing both healthspan and longevity involves temporally modulating this pathway, as its reduction in later life can paradoxically accelerate aging while its cessation in the elderly can rejuvenate function.